Core Viewpoint - Beijing has launched the "National Instrument Beijing Use" plan to promote the evaluation and application of domestic high-end scientific instruments, with a call for proposals for reserve projects from August 19 to September 2, 2025 [1][2]. Policy Updates - The first batch of projects under the "National Instrument Beijing Use" plan aims to enhance the independent innovation capability and competitiveness of high-end scientific instruments in Beijing, with a focus on creating a technology source and industrial cluster for high-end scientific instruments by 2027 [3]. Application Criteria - Eligible applicants include research institutions, universities, healthcare institutions, and technology enterprises registered in Beijing, with a total asset value of scientific instruments not less than 100 million [4]. - Each applicant can submit up to three projects, with each project limited to one product, while each instrument manufacturer can participate with up to three different types of instruments [5]. - The products must be developed and produced by registered instrument companies in Beijing, with specific sales and market conditions outlined for eligibility [6][7]. Support Objectives - The plan includes four main tasks aimed at addressing industry pain points, such as conducting performance evaluations, providing application guidelines, organizing training sessions, and promoting results through media collaboration [8]. - Financial support will be provided upfront upon project approval, with an execution period not exceeding one year [9]. Application Process - The application system is accessible through two online platforms, with the submission window opening on August 19 at 12:00 and closing on September 2 at 17:30 [10].

Core Viewpoint - The article highlights the participation of Huo Tong Instruments at the SynBioCon 2025, emphasizing its leadership in high-end reaction kettle and customized reaction synthesis equipment in China [2][21]. Company Overview - Huo Tong Instruments is headquartered in Shanghai, China, with branches in Hefei, Beijing, Guangzhou, and Taiyuan. The company possesses multiple technical patents and has extensive experience in providing complete solutions from design to manufacturing [5]. - The company integrates research and development, production, and sales, supported by a team of experienced technical personnel and professional after-sales service [5]. Product Summary - **100L Polylactic Acid Reaction Device**: A continuous flow reaction device characterized by continuous feeding, reaction, and discharging, offering high mass and heat transfer efficiency, stability, and safety [6]. - **Resin Synthesis Device**: Features dual gas inlets, high-quality flow meters for accurate measurement, and a deep-cooling reaction kettle with a design temperature of -120°C, along with a user-friendly touchscreen control system [9]. - **Esterification and Polycondensation Reaction Device**: Customizable according to client needs, including high vacuum and high-temperature discharge capabilities [11]. - **Dynamic Tubular Reactor**: Designed for high shear dispersion with a dual heat exchange structure, offering a design pressure of 0-2 MPa and temperature range of -15 to 200°C [14]. - **Intelligent Continuous Flow Platform**: A self-developed system centered around micro-reactors, capable of an annual production capacity of approximately 50 tons [17]. Event Details - The SynBioCon 2025 will take place from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and bio-manufacturing, green chemistry, new materials, future food, and agriculture [21]. - The event will include various activities such as a youth forum, high-level discussions, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [21][22][23].

海能技术 20250818 摘要 北交所市场聚焦稀缺性投资，海能技术作为科学仪器公司，通过内生增 长和外延并购，在有机元素分析和样品前处理领域占据领先地位，相关 会议提前布局新消费行情，并深度分析跟踪公司的边际变化。 北证 50 和专精特新指数近期分别上涨近 7%和 8%，受益于政策支持、 优质企业供给和资金增量，有望实现戴维斯双击。尽管市场曾经历横盘 震荡，但当前时点值得重视，未来或有更多利好因素推动市场。 海能技术的核心竞争力在于政策催化的国产替代趋势和下游客户对国产 设备的需求增长。公司高毛利率的有机元素分析系列和样品前处理产品 是现金奶牛，并通过并购心仪公司扩展业务。 海能技术自 2016 年起投资德国 Gas 公司，并在有机元素分析（食品、 生物疫苗等检测）和样品前处理（食品、药品等检测）领域取得进展， 产品已成为现金奶牛，国内细分市场领先。 海能技术于 2017 年设立悟空仪器，投入近 2 亿研发阴阳色谱技术，目 标是拓展百亿级市场。目前国产化率低，但公司技术指标已接近海外品 牌，阴阳色谱广泛应用于医药、食品、生命科学和化工领域。 Q&A 请介绍一下华源证券北交所团队在 2025 年的线上会议活动 ...

特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 1 3日，超光谱成像产品生产商联光元和完成4亿元A轮融资，本轮由上海联和投资领投，复华科技、高远资本、高维科 技、广合浩信息、韦伯投资跟投。 联 光 元 和 成 立 于 2 0 2 1 年 ， 致 力 于 光 谱 成 像 、 光 源 系 统 与 光 加 工 技 术 的 研 发 ， 为 科 学 仪 器 与 先 进 制 造 领 域 提 供 核 心 产 品。 本轮融资资金将用于推动产品系列化布局和技术产业化应用。根据财联社创投通—执中数据，以2 0 2 5年8月为预测基准 时间，后续2年的融资预测概率为4 4 . 8 2%。 | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 责 编 ： 安 安 | 视 觉 ： 长 艳 柱 子 发 文不易 ， 请 帮小 编点 下 "❤️" ...

导读： 近日，武汉大学科研公共服务条件平台成功安装布鲁克800 MHz固体宽腔核磁共振系统，标志着该校在高端科研设施领域迈入新阶段，进一步提升平台在 有机、无机、聚合物、蛋白质、药物、电池、等研究领域服务能力。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，武汉大学科研公共服务条件平台（Core Faci l it y of Wuhan Uni ver s it y）成功安装 布鲁克800 MHz固体宽腔核磁共振系统 ， 标志 着该校在高端科研设施领域迈入新阶段。作为亚太地区首台成功交付的同类设备，该系统将显著提升平台的高场固体核磁分析能力，为 结 构生 物学、材料科学、清洁能源 等前沿领域的研究提供强大支撑。 th A V | Views X器信息网 tage | 版 权 ： 本 文 部 分 素 材 源 自 网 络 ， 版 权 归 原 作 者 所 有 ， 观 点 代 表 作 者 本 人 ， 不 代 表 本 号 立 场 | 转 载 ： 须 本 号 授 权 ， 请 联 系 主 编 | 来 源 ： 仪 器 信 息 网 | 责 编 ： 安 ...

Core Viewpoint - In the first half of 2025, Haineng Technology reported a revenue of 136 million yuan, a year-on-year increase of 34.87%, and a net profit attributable to shareholders of 5.4715 million yuan, up 139.03% [2][3]. Group 1: Revenue Growth and Product Lines - The main business revenue of Haineng Technology grew by 34.56% compared to the same period last year, driven by the results of previous R&D and market investments, as well as the effectiveness of a diversified product strategy [5]. - All four major product lines (organic element analysis, sample pretreatment, chromatography and spectroscopy, general instruments) achieved revenue growth [5]. - The organic element analysis segment saw a revenue increase of 25.62%, while the chromatography and spectroscopy segment experienced a significant revenue growth of 61.71% [8][9]. Group 2: Domestic and International Business - In the first half of 2025, domestic revenue accounted for 77.04% of total revenue, while international revenue made up 22.96%, with overseas revenue increasing by 22.49% year-on-year [11]. - Haineng Technology has actively expanded its overseas market through international dealer conferences and exhibitions, with products sold in over 130 countries and regions [11]. Group 3: Policy and Market Opportunities - The Chinese government has introduced significant policies in key areas such as pharmaceutical health, energy transition, marine economy, and ecological environment governance, providing broad market opportunities for the scientific instrument industry [12][13][14][15][16]. - Haineng Technology's products are well-positioned to support the pharmaceutical industry, energy sector, and marine economy, contributing to national energy security and low-carbon transition [13][14][15]. Group 4: Strategic Developments and Innovations - In March 2025, Haineng Technology signed a cooperation agreement with Xi'an Jiaotong University to establish a research institute for intelligent analysis instruments, which could enhance the company's product offerings and competitiveness [17]. - The company is developing an instrument control system based on the domestic "Hongmeng system" to align with national strategies for independent innovation and data security [17]. - A project to build an intelligent manufacturing base for scientific instruments with an investment of up to 230 million yuan has been approved, aimed at attracting international talent and enhancing product and technology autonomy [18].

Company and Industry Summary Company Overview - **Company Name**: Haineng Technology - **Reporting Period**: First half of 2025 Key Financial Performance - **Net Profit**: Achieved a net profit attributable to shareholders of 5.47 million, with a growth rate exceeding 100% [2][3] - **Net Profit Excluding Non-recurring Items**: Reached 1.21 million, also showing over 100% growth [2][3] - **Revenue Growth**: Overall revenue increased by 4.87% year-on-year [3] - **R&D Investment**: R&D expenses amounted to 27.47 million, a year-on-year increase of 1.58%, representing 20.19% of total revenue [2][3][7] - **Gross Margin**: Gross margin stood at 63.60%, up by 0.91 percentage points from the previous year [3] Product Performance - **Chromatography and Spectroscopy Products**: - Revenue growth of 62% in the first half of 2025, with the Wukong series nearing 18 million and Gas series exceeding 10 million [2][6] - Significant demand from pet feed, energy, and pharmaceutical sectors [2][6] - **High-Performance Liquid Chromatography (HPLC)**: - Achieved over 60% growth, driven by orders from major pharmaceutical clients like Qilu Pharmaceutical [9] - **Energy Sector**: - Notable performance with a doubling of revenue, particularly from Gas products used in landfill power generation [10] Market Dynamics - **Industry Recovery**: Signs of recovery in food, pharmaceutical, and energy sectors, despite overall weak demand [4][5] - **Future Outlook**: - Optimistic projections for new products with expected annual growth rates of 35% to 50% [4][11] - Anticipation of continued growth in the domestic market for Gas products, projected at 30% to 40% [13] Strategic Initiatives - **R&D Focus**: Continuous investment in R&D to enhance technology and market competitiveness, crucial for long-term growth [7][33] - **Share Buyback**: No further buybacks due to stable stock prices above 15, maintaining a total buyback amount of 30.42 million [2][8] - **International Expansion**: Continued growth in overseas markets, with a 22% increase in the first half of 2025, focusing on Southeast Asia, the Middle East, and Latin America [34] Innovations and Future Products - **New Product Development**: - Collaboration with Xi'an Jiaotong University on cell membrane chromatography technology, with potential applications in drug screening [20] - Development of AI-driven software based on domestic operating systems, with several products expected to launch in 2025 [25][26][27] - **Smart Laboratory Initiatives**: Focus on automating individual testing processes, with ongoing projects in various fields [28][29] Operational Efficiency - **Cost Management**: Decrease in sales and management expense ratios due to revenue growth outpacing expense increases [31][32] - **Manufacturing Base**: Construction of the Shanghai Songjiang intelligent manufacturing base aimed at creating a leading factory in the industry, with a projected annual output value of 1 billion [30] Conclusion - Haineng Technology is positioned for significant growth driven by strong product performance, strategic R&D investments, and a focus on market recovery across key sectors. The company is optimistic about future performance and continues to explore innovative solutions to enhance its competitive edge in the scientific instrument industry.

导读： 活动吸引了近两万观众在线参与，上海新仪产品经理陈硕通过技术分享、真机演示和互动答疑，全面展现了TANK MAX超级微波在样品前处理领域的创新 突破。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 8月8日，上海新仪微波化学科技有限公司（以下简称"上海新仪"）超级品牌日活动成功举办。本次活动以 "快一倍，省一半——探秘超级微波 提速疾控前处理" 为主题，重磅展示了上海新仪最新推出的TANK MAX超级微波化学平台，并邀请行业专家深入解读食品元素检测新标准。活 动吸引了近两万观众在线参与，上海新仪产品经理陈硕通过技术分享、真机演示和互动答疑，全面展现了TANK MAX超级微波在样品前处理领 域的创新突破。 权威解读：食品元素检测新标准 报告题目：GB5009.268-2025《食品安全国家标准 食品中多元素的测定》解读 报告人：深圳市疾病预防控制中心 刘桂华教授 刘桂华老师系统介绍了GB5009.268-2025《食品安全国家标准 食品中多元素的测定》的修订背景与主要内容变化，并重点解读了标准溶液 的配制方法、样品消解流程及操作注意事 ...

QSight 500于2025年最新发布，适用于复杂食品基质中PFAS等痕量污染物的分析工作，它能够简化样品处理步骤，增加设备的正常运行时 间。该设备采用StayClean™自清洁技术，可降低污染风险，减少停机时间，帮助实验室实现"高通量、低维护"的运行效果。 Spotl ight Aurora傅里叶变换红外显微镜采用了全新的高分辨与宽场双光学成像系统，能更快速便捷地定位样品；其Wor k flow工作流显微分 析功能，可简化操作流程，提高分析效率；分体式组合红外显微镜的设计提供了更多灵活性，并能获取多维数据；该设备具备科研级性能与配 置，既满足专家深度操控的需求，也便于日常便捷操作。 导读： 近日，珀金埃尔默公司的QSight 500与Spotlight Aurora分别荣获Labmate 2025年度创新产品奖和最佳成像/光学产品奖。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日，珀金埃尔默的QSight 500 LC/MS/MS 与Spotl ight Aurora 傅里叶变换红外显微镜 分别荣获Labmate 2025年度创 ...

Group 1: Impact of Domestic Substitution Policy - The domestic substitution policy is expected to positively influence company orders, particularly from downstream clients such as government agencies and universities [1] - Historical data indicates that client procurement tends to peak in the third and fourth quarters, prompting the company to actively follow up on project developments [1] Group 2: Shareholder Structure and Risks - The controlling shareholder, Ruiyang Technology, is undergoing a forced liquidation of shares due to a margin call, with an estimated total reduction of no more than 30 million yuan [2] - Current passive share reductions will not lead to changes in the company's control or governance structure [2] Group 3: Long-term Growth Strategies - The company aims to achieve a high market share in existing product categories before expanding into new growth areas such as international markets and acquisitions [2] - Emphasis on addressing customer pain points through innovative applications and enhancing marketing services to improve core competitiveness [2] Group 4: Client Composition and Future Planning - Historically, government institutions have made up a significant portion of the client base, but the company plans to increase the share of enterprise clients as business scales up [2] - The strategy includes providing tailored solutions for large enterprises, enhancing brand reputation through customer satisfaction [2] Group 5: Life Sciences Instrumentation Development - The life sciences instrumentation segment, particularly in life research, is performing well, while progress in medical instruments is slower [3] - Future plans involve leveraging existing technology platforms to penetrate related product markets [3]